Sanofi (SAN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic transformation and business focus

• Transitioned to a pure-play biopharma model, exiting consumer business and focusing on immunology, rare diseases, neurology, and vaccines.

• Achieved industry-leading 11% sales growth through September 2024, with annual sales surpassing $40 billion.

• Sale of Opella to American PE at 14x EBITDA, expecting close to €10 billion in proceeds in Q2 2024, retaining a 48-49% stake for future value.

• Clear capital allocation: increased R&D investment by €700 million in 2024, ongoing dividend growth, and a share buyback planned for 2025.

• Focused business development in core therapeutic areas, with attention to both late-stage and early-stage assets for long-term growth.

Pipeline and innovation

• Three major launches in 2024: Beyfortus (blockbuster in RSV), Altuvio (hemophilia A), and fitusiran, with multiple phase 2 and 3 readouts expected.

• Dupixent projected to reach €13 billion in 2024, with new indications such as COPD driving further growth.

• Itepekimab (IL-33) positioned for COPD, differentiated by targeting former smokers and both high/low eosinophil patients.

• Amlitelimab expected to launch in atopic dermatitis in 2026, with lifecycle management for additional indications.

• Commitment to radioligand therapy through AlphaMedix acquisition, with future expansion under consideration.

Financial outlook and growth drivers

• Strong EPS rebound expected in 2025, supported by continued top-line growth, improved gross margins, and disciplined R&D and SG&A spending.

• R&D spend to remain disciplined, with prioritization and creative financing for phase 3 transitions.

• Low exposure to U.S. IRA and loss of exclusivity, with only 2% at risk through 2030, supporting resilience.

• Dividend increases for 29 consecutive years, with ongoing commitment to shareholder returns.